Protein tyrosine phosphorylation is a ubiquitous, fundamental biochemical mechanism that regulates essential eukaryotic cellular functions. The level of tyrosine phosphorylation of specific proteins is finely tuned by the dynamic balance between protein tyrosine kinase (PTK) and protein tyrosine phosphatases (PTP) activities. Hepatocyte growth factor receptor (HGFR, also known as Met), a receptor PTK, is a major regulator of proliferation, migration, and survival for many epithelial cell types. We report here that receptor type protein tyrosine phosphatase-beta 
Hepatocyte growth factor (HGF), also known as scatter factor (SF), is expressed in numerous tissues (1) (2) (3) (4) (5) , and participates in the regulation of angiogenesis, organogenesis, tissue repair and neural induction (6) . HGF induces random movement/scattering in epithelial cells as well as dissociation, migration, and invasion of cells through the extracellular matrix in vivo (7, 8) . HGF is mitogenic in many normal cell types, including epithelial cells, vascular endothelial cells, and melanocytes. HGF is also a morphogen that induces transition of epithelial cells into a mesenchymal morphology and formation of branched tube-like structures (9, 10) . In keratinocytes, HGF has been shown to promote motility and proliferation (11, 12) . Each of these biological effects exerted by HGF is triggered by stimulation of its cell surface receptor Met (also known as HGF receptor, HGFR), with concomitant activation of downstream effecter molecules (8, 13, 14) . Upon ligand binding, Met autophosphorylates several tyrosine residues in its carboxyl terminal domain.
Met function is controlled by its state of tyrosine phosphorylation (15) (16) (17) . Among the tyrosines within the carboxylterminus, phosphorylation of tyrosines 1234 and 1235, located within the catalytic domain, is required for tyrosine kinase activity (15) (16) (17) . Phosphorylation of tyrosines 1349 and 1356, which are highly conserved among other members of Met family such as Sea and Ron, are necessary for most biological activities of Met (18) (19) (20) . Tyrosines 1349 and 1356, when phosphorylated, serve as multifunctional binding sites for Gab1, Grab2, PI3 kinase, phospholipase C (PLC)-γ, SHP2, and Cbl proto-oncogene. Phosphorylation of tyrosine 1356 is essential for transducing signals for cell motility and morphogenesis (19) (20) (21) .
In addition to its roles in many normal physiological processes, Met also plays important roles in human malignancy. Met was originally identified as TPR-Met oncogene, which possesses ligand-independent tyrosine kinase activity. TPRMet arises from chromosomal fusion of translocated promoter region (TPR) in chromosome 1 with Met carboxyl terminal sequence on chromosome 7 (22, 23) . This rearrangement has been observed in patients with gastic carcinoma (24) . A large body of evidence demonstrates that mis-regulation of Met signaling pathway is involved in many types of human cancers.
Inappropriate expression of HGF/Met autocrine signaling confers increased tumorigenesis and metastatic activity in vivo, and Met expression often correlates with poor prognosis (8, 25, 26) . Met pathway also plays key roles in epithelial-mesenchymal transition (EMT), which is involved in tumor invasion (6) .
Met is one member of a large family of protein tyrosine kinases (PTK). PTK-mediated tyrosine phosphorylation is balanced by the family of protein tyrosine phosphatases (PTPs) (27) (28) (29) . Aberrant regulation of either PTKs or PTPs can lead to abnormal cellular behavior and diseases such as cancer and autoimmunity (30) . There are 107 genes in the human genome that encode for PTPs (81 active enzymes) and 90 genes encode for PTKs (85 active enzymes). Similar levels of complexity suggest that the two families have comparable substrate specificity (31) .
PTKs have been implicated in controlling the amplitude of a signaling response, while PTPs are thought to have important roles in controlling the rate and duration of the response (32, 33) .
Among the PTP super family, there are 38 classical, tyrosine-specific PTPs. These classical PTPs can be further subdivided into 21 receptor type PTPs (RPTPs) and 17 non-transmembrane PTPs. RPTPs contain an intracellular region containing catalytic activity, a transmembrane region, and an extracellular region. All PTPs, regardless of their subtype, contain at least one catalytic domain with a highly conserved active site signature motif ([I/V]HCXAGXXR[S/T]G), where the cysteine residue is absolutely required for catalytic activity. The specificity of PTPs towards substrates can be achieved by their tissue/cell specific expression, subcellular localization/compartmentalization, posttranslational modification, and/or specific interaction between PTP active sites and target sequences (34, 35) .
We report here, that Met tyrosine phosphorylation and function are regulated by receptor type protein tyrosine phosphatase-beta (RPTP-β). RPTP-β directly dephosphorylates Met tyrosine 1356, the major binding site for multiple effecter molecules that drive down-stream signaling pathways.
Materials and Methods
Materials Adult human primary keratinocytes were purchased from Cascade Biologics Inc., (Portland, OR). Human embryonic kidney 293 (HEK293) cells and A431 cells were purchased from ATCC. Met, Erk, and RPTP-β antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Phospho-Met (pY1234/1235), phospho-Met (pY1349), phospho-MEK1/2, and phospho-Erk antibodies were purchased from Cell Signaling Technology (Beverly, MA).
Phospho-Met (pY1349/1356) was purchased from Rockland (Gilbertsville, PA). Phospho-Met (pY1356) was purchased from Abgent (San Diego, CA). RPTP-κ antibody has been previously described (36) . Sodium orthovanadate, hydrogen peroxide, and α-actin antibody were purchased from Sigma. TPRMet cDNA was obtained from Addgene Inc. (Cambridge, MA). Full length human Met cDNA was obtained from Open Biosystems (Huntsville, AL). Met kinase inhibitor II was purchased from Calbiochem (San Diego, CA). Pervanadate was made by mixing 0.5 M sodium orthovanadate with 0.5 M hydrogen peroxide at room temperature for 30 ivaties.
Cell culture Adult human primary keratinocytes were expanded in modified MCDB153 media (EpiLife, Cascade Biologics, Inc., Portland, OR) under 5% CO 2 at 37 o C. HEK293 cells and A431 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) with 1.5 g/ml sodium bicarbonate, supplemented with 10% FBS under 5% CO 2 at 37 o C.
Plasmid construction Full-length human RPTP-β cDNA was subcloned into pShuttle mammalian expression vector (pShuttle RPTP-β, Clontech Laboratories, Inc., Palo Alto, CA). cDNA fragment encoding human TPR-Met fusion protein was generated by PCR from pBABE-puro TPR-Met (Addgene Inc.) as a template using the following primers (Forward primer: 5'-ACCATGGCGGCG-GTGTTGCAGCA-3'; Reverse primer: 5'-TGATG-TCTCCCAGAAGGAGG-3'). PCR products were then cloned into pcDNA3.1-V5-Myc-TOPO with V5 epitome and 6XHis Tag in-frame to generate pcDNA3.1 TRP-Met. cDNA sequences corresponding to the intracellular domain of RPTP-β (amino acid residue 1647 -1997) was amplified by PCR, using pShuttle RPTP-β as template, with forward primer: 5'-TAGGATCCAGCCATGG-TCGAGAAAGACCCT-3'; and reverse primer: 5'-ATGCGGCCGCTCAATGCCTTGAATAGACTGG -3'. The PCR products were digested and cloned into BamHI/NotI sites of pGEX-6P-3 to fuse the GST Tag in-frame. All clones were confirmed by direct DNA sequencing.
Site-directed mutagenesis
The highly conserved cysteine residues (C1904) in the active site of the PTP domain of human RPTP-β were identified by homology to consensus sequence ([I/V]HCXAGXXR[S/T]G) alignment using BLAST (http://www.ncbi.nlm.nih.gov/BLAST/). The highly conserved aspartate residue (D1870) was identified by Laser Gene MegAlign sequence alignment program.
QuickChange XL site-directed mutagenesis kit (Stratagene, La Jolla, CA) was used to generate cysteine 1904 to serine mutation to generate catalytically inactive form of RPTP-β (C1904S). Aspartate 1870 was mutated to alanine to generate the trapping mutant of RPTP-β (D1870A) (37) . Oligonucleotides used for mutagenesis of D1870A and C1904S were: D1870A forward primer: 5'-CGGTGTGGCCAGCCCATGGAGTCCC-3', D1870A reverse primer: 5'-GGGACTCCAT-GGGCTGGCCACACCG-3'; C1904S forward primer:
5'-CCACTGTGGTGCACAGCAGTGC-TGGTGTG-3', C1904S reverse primer: 5'-CAC-ACCAGCACTGCTGTGCACCACAGTGG-3'. All mutations were confirmed by direct DNA sequencing.
Adeno-X expression vector construction and adenovirus production pShuttle RPTP-β was used to generate Adeno-X expression vector using Adeno-X expression system (Clontech Laboratories, Inc., Palo Alto, CA). HEK293 cells were used for adenovirus production (38) .
Preparation of membrane extract and membrane
Met kinase assay Human primary keratinocytes were washed twice with ice-cold hypotonic buffer (20 mM Tris-HCl, pH7.6 with 10 mM NaCl), and scraped from the culture plates in hypotonic buffer supplemented with protease inhibitor cocktail (10 μg/ml aprotinin, 10 μg/ml leupeptin, 10 μg/ml pepstatin A, 1 mM phenylmethylsulfonyl fluoride). Cell suspensions were disrupted in a Dounce homogenizer. Unbroken cells were separated from membrane fraction by centrifuge at 500 x g for 10 minutes. Supernatant was centrifuged at 20,000 x g for 30 minutes. Membrane pellet was resuspended in hypotonic buffer with protease inhibitor cocktail and homogenized by passing the suspension back and forth repeatedly through a 25 gauge needle. Membrane suspension was then supplemented with 100 μM ATP, 0.2% β-mercaptoethanol, and 30 mM MgCl 2 . Kinase reaction was carried out by addition of phosphatase inhibitors and incubating at room temperature for 30 minutes. Laemmli sample buffer was added to stop the reactions. Tyrosine phosphorylation of Met was analyzed by Western blotting using phospho-Met (pY1349/1356) antibody.
Transient transfection of HEK293 cells pShuttle
RPTPs were transiently transfected into HEK293 cells using Superfection, according to manufacturer's protocol (Qiagen, Chatsworth, CA). Cells were treated 24 hours after transfection.
Lentivirus mediated shRNAi silencing of RPTP-β in primary human keratinocytes MISSION TurboGFP shRNA Control Vector and shRNA constructs targeting RPTP-β (5'-CCGGCGGGTGTATCA-GACTAATTATCTCGAGATAATTAGTCTGATA CACCCGTTTTT -3, were purchased from SigmaAldrich (St. Louis, MO). Lentivirus was produced in 293FT cells after transfection of RPTP-β shRNA construct and helper plasmids using Superfection method as described by the manufacturer (Qiagen). Two days after transfection, media from 293FT cells was collected and used to infect human primary keratinocytes to knockdown endogenous RPTP-β.
orthovanadate, and transferred to microfuge tubes. Following 10 minutes incubation at 4 o C, cell homogenates were centrifuged at 14,000 x g for 10 minutes, and supernatants were collected and used as whole cell extracts. Equal amounts of protein from whole cell extracts were resolved by 10% SDSpolyacrylamide gel (Invitrogen, Carlsbad, CA), and transferred to Immobilon-P filter paper (Millipore, Bedford, MA).
Immunoreactive proteins were visualized by enhanced chemifluorescence (ECF) according to manufacturer's protocol (GE Healthcare, Piscataway, NJ). Quantification of chemofluorescence was performed using a STORM PhosphorImager (Molecular Dynamics, Sunnyvale, CA).
GST-RPTP-β-IC fusion protein expression and
purification GST-RPTP-β-IC fusion protein was expressed in E. coli strain BL21 and purified by GST affinity column as previously described (39) . Purity was at least 90%, as judged by SDS PAGE. The concentration of purified protein was determined using Bio-Rad protein assay reagent (Bio-Rad, Hercules, CA).
Preparation of His-Tagged, tyrosine-phosphorylated TPR-Met
Human embryonic kidney HEK293 cells were transfected with pcDNA3.1 TPR-Met using Superfection method as described by the manufacturer (Qiagen). Twenty four hours after transfection, cells were treated with 0.5 mM pervanadate for 30 minutes at 37 o C, washed with ice-cold PBS and lysed with TGH lysis buffer (50 mM HEPES, 20 mM NaCl, 1% Triton X-100, 10% glycerol, pH 7.5) supplemented with Complete Protease Inhibitor Cocktail (Roche, Indianapolis, IN) and 1 mM Sodium orthovanadate (Sigma-Aldrich, St. Louis, MO). Lysates were mixed with Ni-NTA Agarose Nickel-Chelating Resin (Invitrogen, Carlsbad, CA) and incubated overnight at 4°C. Ni-NTA Agarose was washed three times with wash buffer (50 mM HEPES, 20 mM NaCl, 0.1% Triton X-100, 10% glycerol, pH 7.5) and His-Tagged TPRMet was eluted with Elution buffer (50 mM Tris, pH 7.6, 100 mM NaCl, and 10 mM EDTA) and stored in aliquots at -70°C until use.
In vitro direct dephosphorylation of purified TPR-
Met by RPTP-β Purified tyrosine phosphorylated TPR-Met was mixed with purified GST-RPTP-β-IC fusion protein in PTP assay buffer (150 mM NaCl, 1% IGEPAL CA-630, 50 mM Tris, pH 8.0), supplemented with 10 mM DTT, and incubated at 37°C for the indicated times. Dephosphorylation reactions were terminated by addition of Laemmli sample buffer, and the levels of TPR-Met tyrosine phosphorylation were analyzed by Western blot probed with total and phospho-Met antibodies.
Association of TPR-Met with RPTP-β trapping mutant pcDNA3.1 TPR-Met mammalian expression vector was co-transfected into HEK293 cells with pShuttle vector containing either wild type RPTP-β, or active site cysteine mutant RPTP-β (C1904S), or trapping mutant RPTP-β (D1870A) by Superfection method. One day post transfection, HEK293 cells were lysed in TGH lysis buffer supplemented with Complete Protease Inhibitor Cocktail (Roche, Indianapolis, IN). Cell lysates were mixed with Ni-NTA Agarose and incubated overnight at 4°C. Ni-NTA Agarose was washed three times with wash buffer (50 mM HEPES, 20 mM NaCl, 0.1% Triton X-100, 10% glycerol, pH 7.5) and purified HisTagged TPR-Met was eluted from the beads by addition of Laemmli sample buffer.
RPTP-β associated with TPR-Met was detected by Western blot probed with RPTP-β antibody.
Real time reverse transcriptase-polymerase chain reaction (RT-PCR)
Total cellular RNA was purified using EZgene Total RNA Purification Kit according to manufacturer's protocol (Biomiga, San Diego, CA). Reverse transcription of total RNA was carried out using a Taqman Reverse Transcription kit (Applied Biosystems, Foster City, CA). Realtime PCR was performed on a 7300 Sequence Detector (Applied Biosystems), using Taqman Universal PCR Master Mix kit (Applied Biosystems).
Primer/probe combinations were purchased from Applied Biosystems. Target gene mRNA levels were normalized to endogenous housekeeping gene 36B4 mRNA levels.
Results

Inhibition of membrane-associated protein tyrosine phosphatase activity increases Met tyrosine phosphorylation.
We initially investigated regulation of Met by RPTP activity in the membrane fraction from primary human keratinocytes. Inhibition of membraneassociated PTP activity by addition of PTP inhibitors orthovanadate or pervanadate significantly elevated tyrosine phosphorylation of Met. Tyrosine phosphorylation of tyrosines 1349/1356 was elevated 4-6 fold. (Figure 1) . Similar elevations of phosphorylation of tyrosines 1234/1235 were also observed (data not shown). These data suggest that keratinocytes express membrane-associated PTP activity that dephosphorylates Met.
Specific dephosphorylation of Met by RPTP-β in HEK293 cells.
In order to identify membrane-associated RPTPs that dephosphorylate Met, we performed expression screening in HEK293 cells. Based expression profiling of RPTPs in human keratinocytes (36), we chose to characterize six candidate RPTPs. These six RPTPs were separately expressed in HEK293 cells, and their ability to reduce the level of HGFinduced phosphorylation of tyrosine 1349/1356 in endogenous Met was determined. The expression of each candidate RPTP has been confirmed by Western blot (Figure 2A) . Among the six RPTPs, only RPTP-β significantly decreased the level of Met phosphorylation (Figure 2A) . Over-expression of two different catalytically inactive mutant forms of RPTP-β (D1870A and C1904S) or wild-type RPTP-κ, did not decrease Met tyrosine phosphorylation, indicating that reduction of Met tyrosine 1349/1356 requires catalytic activity of RPTP-β ( Figure 2B) .
Over-expression
of RPTP-β reduces Met phosphorylation at tyrosine 1356, but not 1349, in primary human keratinocytes. We next investigated regulation of HGF-induced Met phosphorylation by RPTP-β in primary human keratinocytes. Adenovirus-mediated expression of RPTP-β substantially reduced the level of HGFstimulated Met tyrosine phosphorylation, as detected by phospho-Met tyrosine 1349/1356 ( Figure 3A) and phosphor-Met tyrosine 1356 (Figure 3B) antibody. Expression of RPTP-β had no effect on HGF-induced phosphorylation of Met tyrosine 1349 ( Figure 3A) . Similarly, expression of RPTP-β had no effect on HGF-induced phosphorylation of Met tyrosines 1234/1235 ( Figure 3C) . Expression of RPTP-β in human epidermoid ovarian carcinoma A431 cells also specifically reduced HGF-induced Met phosphorylation at tyrosine 1356 (data not shown). Finally, dephosphorylation of Met by RPTP-β was specific, since expression of RPTP-κ, which dephosphorylates EGFR (36), had no effect on HGF-induced Met phosphorylation at tyrosines 1234/1235, 1349, or 1356 (Figures 3A-3C ). Based on these data, we conclude that RPTP-β specifically dephosphorylates tyrosine 1356. (19, 20) , which leads to activation of Ras/MAP kinase pathway. Since overexpression of RPTP-β reduces tyrosine 1356 phosphorylation, we examined the effects of RPTP-β expression on HGF-induced phosphorylation of MEK1/2 and Erk, in primary human keratinocytes. As shown in Figure 4 , expression of RPTP-β inhibits both MEK1/2 and Erk1/2 phosphorylation. In contrast, over-expression of RPTP-κ does not suppress HGF-induced MEK1/2 or Erk1/2 activation ( Figures 4A and 4B, respectively) .
Over-expression of RPTP-β inhibits HGF-induced
HGF has been shown to modulate angiogenesis through induction of vascular endothelial growth factor (VEGF) (40, 41) . This induction is mediated by activation of the Ras/MAP kinase pathway (42, 43) . Given the ability of RPTP-β to reduce HGF-induced Erk activation, we investigated the ability of RPTP-β to inhibit HGFinduced VEGF gene expression, in primary human keratinocytes. Consistent with the above results, expression of RPTP-β abolishes HGF-induced VEGF mRNA expression ( Figure 4C) .
Knockdown of endogenous RPTP-β increases Met phosphorylation.
We next investigated the effect of knock-down of endogenous RPTP-β on basal and HGF-induced tyrosine phosphorylation of Met, in primary human keratinocytes. Lentivirus mediated expression of shRNA reduced the level of RPTP-β protein approximately 70% (Figure 5A ). This knock-down of endogenous RPTP-β elevated both basal and HGF-stimulated phosphorylation of Met tyrosine 1356 (Figure 5B) , but has no effect on HGFinduced phosphorylation of Met tyrosine 1349 ( Figure 5C ). Furthermore, knock-down of RPTP-b potentiates both basal and HGF-stimulated Erk activation ( Figure 5D ).
RPTP-β directly dephosphorylates Met tyrosine 1356
RPTP-β may act directly or indirectly to reduce phosphorylation of Met tyrosine 1349/1356, in intact cells. To distinguish between these possibilities, we performed in vitro phosphatase assays, using purified intracellular domain of RPTP-β and purified phosphorylated TPR-Met as substrates. In these assays, RPTP-β reduced Met phosphorylation in a dose and time dependent manner. As shown in Figure 6 , phosphorylation of Met tyrosine 1356 was reduced 75% within 15 minutes by RPTP-β. In contrast, RPTP-β had no significant effect on the level of tyrosine 1349 phosphorylation (Figure 6 ). These data indicate that RPTP-β directly dephosphorylates Met tyrosine 1356 in vitro and is consistent with our findings in intact cells ( Figures  3A and 3B) .
RPTP-β substrate-trapping mutant specifically binds Met in intact cells
PTPs and their substrates normally do not form stable complexes. Mutation of a conserved active site aspartic acid (D1870A in RPTP-β) to alanine prevents completion of phosphate ester hydrolysis and therefore traps PTP and substrate in a stable complex (37) . Substrate-trapping mutants have been employed to identify physiological substrates for several PTPs (36, 37, 44) . To further substantiate the role of RPTP-β in Met regulation in intact cells, wild type, substrate-trapping mutant, and active site cysteine mutant RPTP-β were separately coexpressed with His-tagged TRP-Met in HEK293 cell. Pull-down assays were performed with Ni-NTA beads to purify His-tagged TRP-Met from HEK293 lysates and TRP-Met associated proteins were analyzed by Western blot. As shown in Figure 7 , substrate-trapping mutant RPTP-β bound to TRPMet. In contrast, neither wild type nor active site cysteine mutant RPTP-β bound to Met. These data indicate that RPTP-β forms a catalytically active complex with Met in intact cells and Met is a physiological substrate for RPTP-β.
RPTP-β regulates Met-mediated proliferation and migration in human primary keratinocytes.
HGF/Met has been shown to be a key mediator of wound healing through its ability to promote keratinocyte proliferation and migration (11, 12, 45, 46) . Therefore, we investigated the role of RPTP-β in the regulation of keratinocyte proliferation and migration. We found that blockade of Met tyrosine kinase activity by a specific inhibitor (47, 48) suppressed proliferation of primary human keratinocytes ( Figure 8A) . Expression of RPTP-β similarly inhibited cell proliferation ( Figure 8B) . Furthermore, expression of RPTP-β abolished HGFdependent migration of primary human keratinocytes in a scratch assay (Figure 8C) .
Taken together, the above data demonstrate that RPTP-β negatively regulates several important biological functions of HGF/Met via direct dephosphorylation of Met tyrosine 1356.
Discussion
The present study demonstrates regulation of Met tyrosine phosphorylation and function by RPTP-β via specific dephosphorylation of Met tyrosine 1356. Tyrosine 1356 is the major binding site for multiple Met effecter molecules, which mediate down-stream pathways, including Ras/MAP kinase pathway.
Over-expression of RPTP-β suppresses multiple Met functions including proliferation and migration, and inhibits HGFinduced MAP kinase activation and gene expression. Using multiple techniques including substratetrapping and direct in vitro phosphatase assay, we demonstrate that Met is a bona fide substrate for RPTP-β.
RPTP-β is encoded by the ptprb gene, and is composed of an extracellular domain with cell adhesion molecule-like (CAM-like) motif (multiple fibronectin type III-like domains), a transmembrane domain, and a single intracellular PTP domain (49, 50) . RPTP-β is localized to chromosome 12 of the human genome, in a region associated with tumors whose cells have lost contact inhibition (51) . Due to historical reasons (e.g. cloned and named by different groups), RPTP-ξ (encoded by the gene ptprz) is sometimes referred as RPTP-β/ξ or even RPTP-β in the literature. While there are many published studies regarding RPTP-β/ξ, there are only a few published studies on true RPTP-β. Two studies describe in vitro analysis of RPTP-β intracellular domain (52, 53) , and a very recent study indicates that RPTP-β regulates angiopoietin-Tie2 signaling pathway in human endothelial cells. This latter study did not elucidate mechanism of action or identify any RPTP-β substrates (54) . Interestingly, knockout of mouse homologue of human RPTP-β, VE-PTP, is embryonic lethal due to defective angiogenesis (55, 56) . This observation is consistent with the important role that Met plays in angiogenesis (57).
Most RPTPs have two intracellular PTP domains, referred to as membrane-proximal (D1) and membrane distal (D2) domains. Usually the membrane-proximal PTP (D1) domain is catalytically active, while the membrane-distal PTP (D2) domain possesses little, if any, enzymatic activity (58) . The D2 domain is thought to play important roles in substrate recognition or proteinprotein interactions (59) . RPTP-β has only a D1 domain; it lacks a D2 domain. We found that purified RPTP-β maintains its catalytic specificity towards Met tyrosine 1356 in vitro, indicating that a D2 domain is not necessary to confer substrate recognition and specificity.
Biological function of Met is determined by phosphorylation of multiple C-terminal tyrosines. In addition to our finding that RPTP-β dephosphorylates Met, other RPTPs have been shown to influence Met tyrosine phosphorylation (44, 60, 61) . DEP-1 has been shown to preferentially dephosphorylate tyrosines 1349 and 1365 (44) . However, DEP-1 expression did not affect METdependent MAP kinase activation (44) . PTP1B and TCPTP have been shown to dephosphorylate tyrosine 1234/1235 of Met (61) . Using only antisense method, Kulas et al. have shown that knockdown of RPTP-LAR increases tyrosine phosphorylation of insulin receptor, insulin receptor substrate-1, EGFR, and Met. The mechanism for the observed increased phosphorylation was not determined (60) . Our data demonstrate that RPTP-β directly and specifically dephosphorylates Met tyrosine 1356. This finding raises the possibility that fine tuning of ligand-induced Met signaling specificity can be achieved by the levels and activities of sub-sets of RPTPs in different cell types and tissues.
We have previously described direct and specific dephosphorylation of EGFR by RPTP-κ (36) . Therefore, the functions of two important RPTK pathways are specifically controlled by distinct RPTPs. Activation of EGFR or Met leads to both common and distinct cellular responses. There is also cross-talk between these two RTKs. For example, activation of EGFR leads to ligandindependent constitutive activation of Met (62) . These overlapping functions of EGFR and Met allow lung cancer to develop resistance towards EGFR-targeting therapy by switching to Metdependent pathways for proliferation and survival (63) . On the other hand, in Met-amplified gastriccancer cells, selective blocking of Met abolishes the cross-talk activation of EGFR. However, EGFR and downstream signaling pathways (e.g. Ras/MAPK and PI3k/Akt) can still be activated by EGFR ligand in a Met-independent manner (64). Our studies suggest that the availability and abundance of RPTP-κ and RPTP-β will play important roles in regulation of EGFR and Met functions in human physiology and cancer. 
